SI
BIIB icon

Scharf Investments’s Biogen BIIB Stock Holding History

Scharf Investments’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,400
Closed -$1.31M – 43
2016
Q2 		$1.31M Hold
5,400
– – 0.03% 40
2016
Q1 		$1.41M Buy
+5,400
New +$1.43M 0.03% 40

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Scharf Investments's BIIB Position: Q3 2016 in Review

Scharf Investments sold out of Biogen (BIIB) in Q3 2016, closing a stake of 5,400 shares — an estimated $1.31M sold.

Scharf Investments first reported a position in BIIB in Q1 2016 and held it in 2 quarters. The position peaked at $1.41M in Q1 2016. 1,012 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

  • Scharf Investments reported no remaining Biogen position as of Q3 2016 after selling out during the quarter.
  • Scharf Investments sold 5,400 Biogen shares in Q3 2016, an estimated $1.31M.
  • Scharf Investments first reported a position in Biogen in Q1 2016 and held it in 2 quarters.
  • Scharf Investments's Biogen position peaked at $1.41M in Q1 2016.
  • 1,012 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Scharf Investments's 13F filing for Q3 2016, filed 14 Nov 2016.